公开(公告)号：US20230057071A1

公开(公告)日：2023-02-23

申请号：US17786717

申请日：2020-12-03

Applicant: NOVARTIS AG

Inventor： K. Gary J. VANASSE ,  Haiying SUN ,  Mirek DOSTALEK ,  Mikael RINNE ,  Anshu MARATHE ,  Luigi MANENTI ,  Claire FABRE ,  Fariba KHANSHAN

IPC: C07K16/22 ,  C07K16/28 ,  C07K16/24 ,  A61K31/706 ,  A61P35/00

Abstract: Combination therapies comprising TIM-3 inhibitors and TGF-β inhibitors are disclosed. The combinations can be used to treat or prevent cancerous conditions and disorders, including myelofibrosis or myelodysplastic syndrome.

公开(公告)号：US20250041296A1

公开(公告)日：2025-02-06

申请号：US17416008

申请日：2019-12-18

Applicant: NOVARTIS AG

Inventor： Nelson GUERREIRO ,  Astrid JULLION ,  Christophe MEILLE ,  Claire FABRE

IPC: A61K31/506 ,  A61K31/553 ,  A61K31/635 ,  A61K31/704 ,  A61K31/7068 ,  A61K39/395

Abstract: The present invention relates to the HDM2-p53 interaction inhibitor (S)-5-(5-Chloro-1-methyl-2-oxo-1,2-dihydro-pyridin-3-yl)-6-(4-chloro-phenyl)-2-(2,4-dimethoxy-pyrimidin-5-yl)-1-isopropyl-5,6-dihydro-1H-pyrrolo[3,4-d]imidazol-4-one (HDM201) for use in the treatment of hematological tumors, wherein the drug is administered following an extended low dose regimen characterized by a higher dose during induction and a lower dose during consolidation.

公开(公告)号：US20230056470A1

公开(公告)日：2023-02-23

申请号：US17786265

申请日：2020-12-03

Applicant: NOVARTIS AG

Inventor： Mirek DOSTALEK ,  Claire FABRE ,  Fariba KHANSHAN

IPC: C07K16/22 ,  C07K16/28 ,  A61P35/00 ,  A61K45/06 ,  A61K39/395

Abstract: Therapies using TGF-β inhibitors and/or PD-1 inhibitors are disclosed. These drugs at certain doses (including flat dosing) and regimens can be used to treat or prevent proliferative diseases such as solid tumors, including pancreatic cancers. Further combination and uses thereof are also disclosed.